Ono Pharmaceutical pays $80M for regional rights to Biohaven's IgG degraders
Japan's Ono Pharmaceutical is paying $80 million upfront for regional rights to three of Biohaven's IgG degraders, including BHV-1300, a phase 3 candidate for Grave's disease. The licensing agreement covers Japan and select Asian regions.
